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Proteomics is a nascent technology with much to de-
velop and much to oﬀer. Both the biotechnology and
pharmaceutical arenas will be highly impacted by the new
window proteomics is opening. This area of studies will
permit us to identify, characterize, and quantify proteins
on a massive scale, resulting in a fundamental change
in biological and chemical approaches to understanding
proteins and even the ability to address new important
questions. Advancing the tools of proteomic technology
further is of major interest to biotech and pharma com-
munities. Proteomics does require substantial resources
and infrastructure investment; therefore, the eﬀort will be
greatly enhanced by the coordinated participation of all
involved, in both academia and industry. Such resources
and coordination are only slowly becoming available on
the scale necessary to make a signiﬁcant impact and the
Human Proteome Organization (HUPO) is at the van-
guard of these eﬀorts. The focus of this piece is on the
promises and the challenges of proteomics in biotech-
nology, drug discovery, and diagnostics. Additional view-
points from a business and scientiﬁc strategic standpoint
onwherethingsareheadedintheproteomicsmarketplace
will be discussed.
Now that the human genome has been sequenced, the
study of the proteins that carry out the gene’s instruction
is likely to be the next frontier in biomedical research.
Surprisingly, the human genome appears to contain per-
haps fewer than 30000 genes, which is far fewer than the
original estimates. Enter the world of proteomics. Pro-
teomics includes not only the identiﬁcation and location
of proteins, but also the determination of networks, in-
teractions, activities, and functions. A single gene can en-
code multiple proteins through a variety of translational
and post-translational mechanisms. In addition, the same
protein can assume multiple forms. Finally, the same pro-
tein may have multiple functions, depending on its cel-
lular environment and associated networks. All of these
possibilitiesresultinaproteome(theensembleofproteins
related to a genome) estimated to be at least an order of
magnitude more complex than the genome itself.
DRUG DISCOVERY
Drug discovery is a prolonged process that uses a
variety of tools from diverse ﬁelds. Proteomics as an in-
terdisciplinary ﬁeld combinesboth biology and chemistry
and the emerging areas of high-throughput automation
and bioinformatics. Promising technologies, as part of
the arsenal of proteomic techniques, are advancing the
utility of proteomics in drug discovery process. The disci-
pline of proteomics is currently divided into three distinct
classes that are indispensable to drug discovery: pro-
ﬁling proteomics, functional proteomics, and structural
proteomics. The tools in protein drug discovery range
from 2D/mass spec analyses to multiplex protein pro-
ﬁling to structure-based drug design. Vital to the func-
tional/structural proteomics eﬀorts are high-throughput
cloning, protein expression, protein production, and pro-
tein puriﬁcation.
BIOTECHNOLOGY
Experimental studies related to protein fractionation
and separation, qualitative and quantitative protein anal-
yses, identiﬁcation/characterization of the composition of
protein complexes and organelles seem likely to enhance
our understanding of dynamic cellular processes, thus,
making the proteome a less formidable challenge. Look-
ing ahead we expect protein arrays to play a powerful
important role and that novel protein therapeutics will
emerge.
Proteinproduction
The challenge of studying proteins in a global way
is driving development of new technologies for system-
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function. Experimental uses of proteins for structural and
functional studies typically require milligram amounts
in puriﬁed form. Protein expression, production, and
puriﬁcation are fundamental processes in these stud-
ies; however, they have typically only been applied on
a case-by-case basis to proteins of interest. Strategies are
emerging to industrialize these processes and overcome
the limitations imposed by conventional methods. Paral-
lel processing, miniaturization approaches, array spotting
techniques all will signiﬁcantly contribute to making pro-
teomics more main stream.
Antibodies
To deﬁnethe proteome ofanorganism,thereis aneed
for robust reproducible methods for the quantitative de-
tection of all the polypeptides in a cell. Because of their
high-aﬃnity, speciﬁcity, and their ability to bind virtually
to any protein, antibodies appear particularly promising
as the receptor element in protein-detection arrays. For
proteomic-scale analyses and fabrication of high-density
arrays, the ability to produce and isolate antibodies en
massetoalargenumberoftargetmoleculesiscritical.The
high-throughput issues of recombinant proteins apply
equally well to antibody molecules to generate proteins
for microarrays and antibodies for immunolocalization
and/or functional analysis utilizing highly sensitive detec-
tion protocols.
DIAGNOSTIC
Biomarkers have been in widespread use for many
years, but the ﬁeld has emerged in its own right over
the last decade, propelled by proteomics. It is antici-
pated that biomarker discovery will shift more to anal-
ysis of bioﬂuids and, to a lesser extent, tissue samples
from relevant patient populations as an initial approach.
Furthermore, biomarker panels will be selected based on
their prominence in discriminant analysis combined with
their amenability to routine standardized clinical tests.
Biomarkers derived from proteomics have the potential
to dramatically reduce both the time and the risk involved
in target discovery and validation, better understand dis-
easemechanisms(noveltherapeuticmodalities),diagnose
and track diseases and drug actions, and, ﬁnally, proﬁle
patients for personalized medicine. Looking for biomark-
ers/targets with the right tools in the right place should
greatly improve success rates and shorten the develop-
ment cycle.
HUPO INITIATIVES
No discussion is complete without mentioning the ef-
forts of HUPO and the various projects that are under-
way. HUPO has galvanized the scientiﬁc community both
nationally and internationally to organize several human
proteome projects (plasma, liver, brain, etc), even a pilot
program for the mouse and rat liver proteome. Under
thepatronageofHUPOacademiclabs,industrialpartners
and regional HUPO societies soon will report signiﬁcant
advances in protein science.
CONCLUDING REMARKS
Proteomics is changing the way we look at and deal
with proteins (diversity in structure, function, and dy-
namic range). Various instrumentation advancements
and analytical tool improvements are a must to achieve
the human proteome map. Many of the methods de-
scribed in the literature were developed either as a
proof-of-concept or as a pilot program in response to
the proteomic challenge. These technologies have been
proven to be able to deliver, to various degrees of course.
The eﬀectiveness of current or future methodologies will
be determined by resolving the many problems that will
be encountered. The success rate with “diﬃcult” proteins
willbethetruelitmustestforanyhigh-throughput,global
analyses systems. It is unlikely that the processes in its
current form are going to meet the demand for proﬁling
structural or functional proteomic work. Improvements
are needed to gain economies of scale and eﬃciencies
in protein manipulation. Parallel processing and generic
methods are required to achieve a systematic and thor-
ough evaluation of protein function. The complexity of
this eﬀort is compounded by the large number of gene
products comprising the proteome. At the end, sub-
protein populations (subproteome) will become a com-
modity, which can be delivered as a product rather than
a service. This fundamental change is vital if the promises
of the proteome are to be realized.
The immediate impact of proteomics and the fruits of
proteomics are likely to be the following:
(1) proteomicswillcomplementexisting approachesto
drug discovery/diagnostics,
(2) rewards of proteomics in early discovery eﬀorts will
be realized 8–10 years of the typical drug develop-
ment cycle,
(3) proteomic studies beneﬁts will be seen sooner at
later-stage uses for drugs on or close to market
(biomarkers for eﬃcacy, toxicity, diagnostic, etc).
As ﬁnal thoughts, it is hard to perceive that a certain
technology or one system will dominate the landscape of
proteomics. Proteomics will become an integral compo-
nent of systems biology to facilitate better-informed and
earlier R&D decisions. Perhaps proteomics is like house-
work, it will never end!
M. Walid Qoronﬂeh2004:3 (2004) Editorial 123
M. Walid Qoronﬂeh earned an MS in
Chemistry from Illinois and a PhD in
Microbial Genetics from The University
of Louisville Medical School. After post-
doctoral work at the University of Geor-
gia in molecular biology, he started his
career in the pharmaceutical industry in
1989. Later, he received an MBA with an
emphasis on R&D and technology man-
agement from Penn State University. As
a scientist at SmithKline Beecham, he worked in the areas of
heterologous gene expression/protein engineering and studied
the molecular aspects of HIV drug resistance. As a Sr. Sci-
entist/Group Leader with Sterling-Winthrop Pharmaceuticals,
he played a key role in the development of collagenases as a
target for HTS/structure-based drug design studies where the
team advanced two drug candidates. As a Scientist Manager
in the Structural Biochemistry Program at the NCI his activi-
ties focused on functional genomics, antivirals and anticancers
wherehewasinvolvedintargetidentiﬁcation/validationandde-
veloped assays to several enzymes. He established HT protein
expression and protein puriﬁcation capabilities for structure-
based drug design eﬀorts. As a Director of Antiinfective De-
velopment at AntexPharma he established the company’s HTS
capability and was responsible for hit-to-lead and lead opti-
mization eﬀorts. His eﬀorts and the screens identiﬁed a broad-
spectrum and speciﬁc agent antibiotics. Currently, he is the
Senior Director for Drug Discovery & Proteomics at Perbio
Science Bioresearch Division. He is engaged in various as-
pects of proteomic research (methods or technology develop-
ment). These eﬀorts resulted in several commercial products
being available in the market place. He has 40 peer-reviewed
papers and over 50 published abstracts to his credit. He is
a featured speaker at national and international conferences.
Recently, M.W. Qoronﬂeh in collaboration with the Medical
College of Wisconsin in Milwaukee, University of Wisconsin-
Madison, and other partners were awarded an NHLBI grant to
establish a proteomic center at MCW.
∗ E-mail: walid.qoronﬂeh@perbio.com